Literature DB >> 20731650

Onset of psoriasis following treatment with tocilizumab.

S Laurent, J-M Le Parc, T Clérici, M Bréban, E Mahé.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20731650     DOI： 10.1111/j.1365-2133.2010.10005.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  15 in total

Review 1.  Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.

Authors:  Éric Toussirot; François Aubin
Journal:  RMD Open       Date:  2016-07-15

2.  Is tocilizumab safe in Kaposi sarcoma? A complex association among rheumatoid arthritis, psoriasis, and Kaposi sarcoma.

Authors:  Alice Verdelli; Diletta Bonciani; Veronica Bonciolini; Marzia Caproni
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

3.  Induction of Alternative Proinflammatory Cytokines Accounts for Sustained Psoriasiform Skin Inflammation in IL-17C+IL-6KO Mice.

Authors:  Yi Fritz; Philip A Klenotic; William R Swindell; Zhi Qiang Yin; Sarah G Groft; Li Zhang; Jaymie Baliwag; Maya I Camhi; Doina Diaconu; Andrew B Young; Alexander M Foster; Andrew Johnston; Johann E Gudjonsson; Thomas S McCormick; Nicole L Ward
Journal:  J Invest Dermatol       Date:  2016-10-27       Impact factor: 8.551

4.  Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience.

Authors:  Rahul Sehgal; Erik J Stratman; Jonathan E Cutlan
Journal:  Clin Med Res       Date:  2018-04-02

Review 5.  Psoriasis: Past, Present, and Future.

Authors:  Allison C Billi; Johann E Gudjonsson; John J Voorhees
Journal:  J Invest Dermatol       Date:  2019-11       Impact factor: 8.551

Review 6.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

Review 7.  Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.

Authors:  Michitaro Hayakawa; Keisuke Izumi; Misako Higashida-Konishi; Mari Ushikubo; Masako Tsukamoto; Kumiko Akiya; Kazuhiro Araki; Hisaji Oshima
Journal:  Rheumatol Int       Date:  2018-10-24       Impact factor: 2.631

8.  Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Authors:  Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  JCI Insight       Date:  2016-12-08

9.  TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Authors:  Sara Jiayang Li; Lourdes M Perez-Chada; Joseph F Merola
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2018-11-21

10.  Pathological role of interleukin-6 in psoriatic arthritis.

Authors:  Atsushi Ogata; Atsushi Kumanogoh; Toshio Tanaka
Journal:  Arthritis       Date:  2012-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.